What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Immune system
- Gene
Type 1 diabetes, Diabetes mellitus, Immunology, Internal medicine and Insulin are his primary areas of study.
His Type 1 diabetes research is multidisciplinary, incorporating perspectives in Clinical trial, C-peptide, Intensive care medicine, Teplizumab and Immunopathology.
The Diabetes mellitus study combines topics in areas such as Natural history and Relapsing remitting.
As part of his studies on Immunology, he often connects relevant areas like Disease.
His research in Internal medicine intersects with topics in Anti-CD3 monoclonal antibody, Endocrinology and Surgery.
Many of his research projects under Insulin are closely connected to Population with Population, tying the diverse disciplines of science together.
His most cited work include:
- Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus (1061 citations)
- Genetics, pathogenesis and clinical interventions in type 1 diabetes (805 citations)
- Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. (599 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Type 1 diabetes, Immunology, Diabetes mellitus, Internal medicine and Endocrinology.
His Type 1 diabetes research includes themes of Clinical trial, Insulin, C-peptide, Teplizumab and Disease.
Immune system, Autoimmunity, Antigen, Autoimmune disease and Antibody are among the areas of Immunology where Kevan C. Herold concentrates his study.
His study in Antigen is interdisciplinary in nature, drawing from both T cell and Cytotoxic T cell.
His Diabetes mellitus study combines topics in areas such as Autoantibody, Randomized controlled trial, MEDLINE and Intensive care medicine.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Oncology.
He most often published in these fields:
- Type 1 diabetes (47.62%)
- Immunology (45.08%)
- Diabetes mellitus (43.49%)
What were the highlights of his more recent work (between 2017-2021)?
- Type 1 diabetes (47.62%)
- Diabetes mellitus (43.49%)
- Internal medicine (40.63%)
In recent papers he was focusing on the following fields of study:
Kevan C. Herold mostly deals with Type 1 diabetes, Diabetes mellitus, Internal medicine, Immunology and Autoantibody.
His Type 1 diabetes study combines topics from a wide range of disciplines, such as Area under the curve, Insulin, C-peptide, Teplizumab and Oral glucose tolerance.
His Diabetes mellitus research incorporates themes from Disease, Immune checkpoint inhibitors, Pancreatitis and Pharmacology.
His studies deal with areas such as Gastroenterology and Endocrinology as well as Internal medicine.
Kevan C. Herold has researched Endocrinology in several fields, including Risk predictor and Enantiomer.
His Immune system, Antibody, Autoimmunity and CD8 investigations are all subjects of Immunology research.
Between 2017 and 2021, his most popular works were:
- Reprogramming human T cell function and specificity with non-viral genome targeting (283 citations)
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes (155 citations)
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors (152 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Immune system
- Gene
Kevan C. Herold mainly investigates Diabetes mellitus, Type 1 diabetes, Immunology, Disease and T cell.
His Diabetes mellitus research incorporates elements of Area under the curve, Internal medicine, Pharmacology, Autoantibody and Anti-thymocyte globulin.
His biological study spans a wide range of topics, including Endocrinology and Enantiomer.
The various areas that he examines in his Type 1 diabetes study include Teplizumab, Monoclonal and Insulin.
As part of one scientific family, he deals mainly with the area of Disease, narrowing it down to issues related to the Intensive care medicine, and often Clinical trial, Natural history and Disease progression.
His T cell research is multidisciplinary, relying on both CD8 and Antigen.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
